Inozyme Pharma Stock

inozyme.comHealthcareFounded: 2016Funding to Date: $115.85MM

Inozyme Pharma is a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases.

Learn more about Inozyme Pharma IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Inozyme Pharma.

Register Today

Team

Management Team

Henric Bjarke

Chief Operating Officer & Senior Vice President

Stephen Basso

Vice President of Finance

Joseph Schlessinger Ph.D

Co-Founder & Chairman

Steven Jungles

Chief Technical Operations Officer & Senior Vice President

David Thompson

Senior Vice President & Chief Scientific Officer

Eric Yuen MD

Chief Medical Officer & Senior Vice President

Axel Bolte

Co-Founder, Chief Executive Officer, President & Board Member

Ruhi Ahmed Ph.D

Vice President of Regulatory and Government Affairs

Demetrios Braddock Ph.D

Scientific Founder, Chairperson of Scientific Advisory Board and Board Observer

Board Members

Axel Bolte

Joseph Schlessinger Ph.D

Rob Hopfner

Demetrios Braddock Ph.D

Martin Edwards MD

Novo Holdings

Ruchita Sinha

Sanofi-Genzyme Bioventures

Edward Mathers

New Enterprise Associates

Reinaldo Diaz

Longitude Capital

Sarah Bhagat Ph.D

Sofinnova Investments

Other companies like Inozyme Pharma in the Healthcare sector

Sector

Last Round Est. Valuation

$2.15B

Sector

Last Round Est. Valuation

$3.67B

Sector

Sector

Last Round Est. Valuation

$317.32MM

Sector

Last Round Est. Valuation

$334.19MM

Mammoth Biosciences

Sector

Last Round Est. Valuation

$1.08B

Sector

Last Round Est. Valuation

$1.59B

Sector

Last Round Est. Valuation

$4.26B

Sector

News

Business Wire 11/14/2019

Inozyme Pharma Expands Medical Leadership Team

Inozyme Pharma today announced the addition of three industry veterans to its leadership team.

Frequently Asked Questions